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Conclusions: SVC syndrome because of CVO is now amenable to
interventional treatment. These patients go back to normalcy and
maintenance hemodialysis immediately after the procedure. This
is the largest reported series in India of SVC syndrome/CVO
treated by Endovascular approach.
Endovenous Laser therapy by Laser blast
technique for treating varicose vein e Experience
of the largest series of 6,018 patients
N.N. Khanna, Suparna Rao, Obiora Ajuluchukwu
Indraprastha Apollo Hospital, New Delhi, India
Background: Venous reflux is seen in about 8% of adult popula-
tion. Till now surgery was considered to be the gold standard.
Recently, Endo-Venous Laser Therapy (EVLT) has been used with
great success with a recurrence rate of less than 7% after two
years. This abstract discusses our results of 6018 successive cases
of varicose veins treated by novel laser blast technique.
Methods: 6018 patients of severe sapheno-femoral incompetence
were treated by EVLT using 25 watts Diode laser machine. Venous
access was gained near the ankle using duplex scanning. A 5F
sheath was inserted into the great saphenous vein and advanced
upto 2 inches below the saphenofemoral junction. 810 mmbare tip
laser fibres were used and was advanced through the sheath. The
position of the fibre tip was confirmed by the red light (at the tip)
which is seen through the skin. The sheath and the fibre were
then withdrawn while delivering the laser energy at a rate of
about 1 mm/sec delivering about 12joules/pulse/sec. Individual
perforators, short saphenous vein and extra-axial varicosities
were treated and the completeness of the procedure was assessed
by angiographic guidance. Patients were followed-up by duplex
scan after one day, one month, six months and one year.
Results: N ¼ 6018; Great Saphenous Vein (GSV) 3948, Short Saphe-
nous Vein (SSV) 1520 and Both (GSV + SSV) 1428, Perforators 783.
Adjuvant Sclerotherapy / Perforator Ligation / ablation 140;
Wavelength of LASER 810mm and System BIOLITIC.
Avg. lasering time 3 -5 mins, and avg. procedure time 62 mins
Procedural Success 6018/6018, Immediate Mobilisation 6018/
6018
Complications included: DVT 17/6018, Pain 1268/6018, Swelling
78/6018, Ecchymosis 906/6018 and Pulmonary Embolism 0/6018.
Follow Up: Freedom from recurrence at 6mnths - 97%; 12mnths
- 94%.
Conclusion: EVLT is an outdoor, quick, successful minimally
invasive procedure to treat venous varicosities due to sapheno-
femoral reflux. The patients'compliance is excellent, with very
low recurrence rate of about 6%.
Prognostic value of plasma N-terminal pro-Brain
natrituretic peptide and high sensitivity troponin
T in patients with sepsis; correlation with C
reactive protein level and 2D echocardiography
P.T. Suhail, G. Vijayaraghavan, V.K. Sureshkumar
Kerala Institute of Medical Sciences (KIMS), Trivandrum, Kerala, India
Background: Increased levels of pro-BNP and Hs trop T as a pre-
dictors of cardiac dysfunction and prognosis in congestive heart
failure and ischemic heart disease have been identified. But only a
few studies identifytheir role in septicmyocardial injury. Base line
parameters and the level of Hs Troponin T in distinguishing septic
myocarditis from acute coronary events are also not well studied.
Aim: To determine the role of the pro-BNP and hS troponin T in
the context of outcome of septic patients; to analyze their corre-
lation with c reactive protein level and 2d echocardiogragraphy
findings. Base line parameters and level of hS troponin in helping
to distinguish septicmyocarditis from acute coronary events were
also evaluated.
Methods and Results: 1OO consecutivepatients with sepsis were
included. Levels of pro-BNP, Hs troponin T, C reactive proteinwere
measured on the day of diagnosis of sepsis. 2d echocardiography
was performed on the same day and repeated on the day of
discharge. Patients had myocardial injury diagnosed by elevated
Hs Troponin T, and elevated pro-BNP. Patients with Pro-BNP level
>4000 pmol/L had increased morbidity and the level >25000 pre-
dicted 90% mortality. Level of hS troponin T showed a linear
correlation with pro- BNP levels, but pro BNP was more sensitive
in prognostication. Level of Hs Troponin T >500 was indicative of
an acute coronary event rather than septic myocarditis. This
correlatedwith ECG and echo findings and later with coronary
angiogram in selective patients.
Conclusion: Pro-BNP and Hs troponin T may serve as useful lab-
oratory marker to predict survival in patients with sepsis. Serial
evaluation of Hs troponin T may also help to distinguish septic
myocardial injury from acute coronary events.
Interventional approach for management of acute
deep vein thrombosis (DVT)
N.N. Khanna, Suparna Rao, Obiora Ajuluchukwu
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Background: Although DVT of calf veins is most common, 40% of
DVTs occur in the femoral and iliac veins and have a high risk of
pulmonary thromboembolism and Post Thrombotic Syndrome
(PTS), which can be avoided by timely interventional manage-
ment. Catheter Directed Thrombolytic Therapy (CDTT) and
Pharmacomechanical Catheter-Directed Thrombolysis (PCDT),
(combination of CDTT with percutaneous mechanical thrombec-
tomy) is the best possible solution. This dual mechanism of action
enhances the efficiency and rate of thrombus removal. It also
uncovers the May Thurner syndrome in many cases.
Methods: Diagnosis was made by Duplex scan and venography.
Patients with DVT extending to common femoral vein and above
were included. Popliteal vein was accessed under Duplex guid-
ance and a 6F sheath was introduced. Suction thrombectomy was
done using 6Fmultipurpose guiding catheter and amulti side hole
infusion catheter was used to deliver continuous intra-clot tissue
infusion of tPA for 24-48 hrs. More than 50% angiographic clear-
ance of the thrombus was used as criteria of success and if May
Thurner syndrome was uncovered, left common iliac vein was
stented by self-expanding stents. Patients were then kept on oral
anticoagulants, to maintain an INR of 2.5-3.5.
Results: N ¼ 26; Duration of DVT:  14 days.
Involvement: Femoral Vein ¼ 26 ; External Iliac Vein ¼ 20 ;
Common Iliac Vein ¼ 13 ; IVC ¼ 3
Procedure: Thrombolytic agent tPA.
Aspiration Thrombectomy (AT) ¼ 26/26 ; CDTT ¼ 26/26.
Reduction of Thrombus load:
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AT CDTT Stenting
Femoral vein 60% 100% 2/26
External iliac vein 60% 100% 6/26
Common iliac vein 50% 80% 8/26
IVC 25% 60% -
Follow up: Mean e 1 year (8monthse 19months); Recurrence of
DVT e 2/26; PTS e 0/26 and Pulmonary Embolism e 0/26.
Conclusion: Interventional approach for acute DVT is successful,
promising and feasible. Rapid removal and lysis results in pre-
serving venous valve functions and reducing the incidence of PTS.
Stem cell augmentation for cardiovascular risk in
Rheumatoid Arthritis: STAR study
A. Syngle, N. Garg, P. Krishan, I. Verma
Healing Touch City Clinic Chandigarh, Punjabi University, Patiala, India
Background: Bone marrow derived stem cells, endothelial pro-
genitor cells (EPCs), protect against atherosclerotic vascular
damage. However, EPCs are depleted in RA and contribute to the
enhanced cardiovascular (CV) risk. Therapeutic potential of aug-
menting EPCs to treat the heightened CV risk of RA has not yet
been exploited. We aimed to investigate the effect of rosuvastatin
on EPCs population, endothelial dysfunction, nitrite, adhesion
molecules and on markers of inflammation in RA.
Methods: 50 RA patients, randomized to receive 24 weeks of
treatment with rosuvastatin (10mg/day, n¼25) or placebo (n¼25)
as an adjunct to existing stable antirheumatic drugs. EPCs (CD34+/
CD133+) were quantified by Flow Cytometry. Flow mediated
dilatation (FMD) was assessed by AngiodefenderTM (Everest
Genomic Ann Arbor, United States). Inflammatory measures
included DAS28, CRP, ESR, Pro-inflammatory cytokines (TNF-a, IL-
6 and IL-1), levels of serum nitrite, lipids and adhesion molecules
(ICAM-1 and VCAM-1) was done at baseline and after treatment.
Results: At baseline, inflammatory measures, pro-inflammatory
cytokines, adhesion molecules and nitrite levels were elevated
and EPCs and endothelial function were impaired among both
groups. At 24 wks: DAS28, ESR, CRP, TNF-a, IL-6, nitrite and ICAM-
1 improved significantly in rosuvastatin group. EPCs increased
significantly after treatment with rosuvastatin as compared with
placebo. FMD improved significantly in the rosuvastatin group.
Rosuvastatin exerted positive effect on lipids. Significant inverse
correlation observed between EPCs and CRP, TNF-a, ICAM-1and
FMD after rosuvastatin treatment.
Conclusion: First study to show that rosuvastatin augments EPCs
population in RA mediated by lowering the cytokine levels, which
downregulates adhesion molecule, CRP and nitric oxide produc-
tion. This defines a novel mechanism of rosuvastatin treatment in
RA: the augmentation of EPCs with improvement in inflammatory
disease activity and endothelial dysfunction.
New oral anticoagulants in atrial fibrillation
L. Sumithra, S.S. Iyengar, V. Subash Chandra, G. Sridhara,
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Background: Atrial fibrillation (AF) is a common arrhythmia, and
is an important cause of stroke. Risk of stroke and bleeding need
to be assessed before initiating anticoagulant treatment. New oral
anticoagulants (NOACs) are available now as an alternative to
vitamin K antagonists (VKA).
Objective: Our objective was to study the incidence of valvar AF
versus nonvalvar AF, the scores for risk of stroke and bleeding and
the use of NOACs in a tertiary case hospital.
Methods: Cases of atrial fibrillation hospitalized or seen in out
patient over a period of two years were studied. CHA2DS2VASc
and HASBLED scores were applied to all cases of nonvalvar AF.
Creatinine clearance was calculated by Cockroft formula.
Results: There were 60 patients of AF, 30 being male. Mean age
was 66.6 years overall, 62.6 years for male and 70.6 for female
patients. 43 (71.6 %) patients had nonvalvar AF and 17 (28 .4 %) had
valvar AF. OF 17 cases of valvular AF, 04 had prosthetic valve and
all were on VKA.
For the 43 patients of nonvalvar AF, the mean CHA2DS2VASc
score was 2.8 and the mean HASBLED score was 1.5. Fifteen pa-
tients received dabigatran. Of these 15 patents, one shifted from
VKA to dabigatran as she found frequent INR monitoring incon-
venient. 35 opted for VKA for economic reasons and 5 declined to
have any anticoagulation. In one patient, oral anticoagulation was
not started since he had subdural hematoma. In four patients, oral
anticoagulation was not indicated as the CHA2DS2VASc score was
0. Amongst 15 patients who received dabigatran, 11 were on 110
mg twice a day dose because of age, renal dysfunction and body
weight, 4 were on 150 mg twice a day. All these patients tolerated
dabigatran well.
Conclusion: There were more nonvalvar AF cases than valvar AF
and female patients were older. CHA2DS2VASc and HASBLED
scores are easy to apply and help in decision making on initiation
of oral anticoagulants in nonvalvar AF patients. Dabigatran is an
attractive alternative to VKA to prevent stroke in nonvalvar AF.
Cost, compliance, comorbidites and coadministration of other
drugs may be constraints for the use of NOACs.
To study Troponin T levels and its significance in
relation to mortality and morbidity in acute
ischemic stroke
A. Lalchandani, Anand Kumar Singh, P. Paliwal, M. Godara,
M. Naveen, T. Midha, A. Garg, A.N. Singh, P. Singh
PG Institute of Medicine, GSVM Medical College, Kanpur, India
Background: Troponin T levels have been shown to have a very
good correlation with cardiac stroke or myocardial infarction. In
this study Troponin T levels were evaluated in patients of acute
ischemic stroke.
It follows that Troponin T levels must have a correlation with
morbidity and mortality in these patients (pt.).
Methods: Pt of acute ischemic stroke confirmed by CT scan or MRI
within 72 hr of stroke onset, admitted in medicine ward of L.L.R
and associated hospital in G.S.V.M medical college Kanpur and
measurement of cTn T between 12-72 hr of stroke onset. There
were 45 patients in study who were admitted over a period of
January 2010 to September 2011.
Results: 17.8% of patients in study show rise in troponin T
(>0.01mcgm/dl) out of which 37.5% pt had poor outcome while
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